Phase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinoma

Authors:
  • SSSudarshan Sharma
    Sudarshan Sharma
  • SGSharad Ghamande
    Sharad Ghamande
  • MGMichael S. Gordon
    Michael S. Gordon
  • SPSalvatore A. Del Prete
    Salvatore A. Del Prete
  • IRIsabelle Ray-Coquard
    Isabelle Ray-Coquard
  • EKElzbieta Kutarska
    Elzbieta Kutarska
  • HLHua Liu
    Hua Liu
  • HFHoward Fingert
    Howard Fingert
  • XZXiaofei Zhou
    Xiaofei Zhou
  • HDHadi Danaee
    Hadi Danaee
  • RSRussell J. Schilder
    Russell J. Schilder

Abstract
No abstract available
Funding Information
  • Millennium Pharmaceuticals, Inc.

This publication has 22 references indexed in Scilit: